Daniel J Becker1,2, Temitope Rude1,3, Dawn Walter1,4, Chan Wang4, Stacy Loeb1,4, Huilin Li4, Shannon Ciprut1,3,4, Matthew Kelly1,3,4, Steven B Zeliadt5, Angela Fagerlin6,7, Herbert Lepor2,3, Scott Sherman1,2,4, Joseph E Ravenell4, Danil V Makarov1,4,8. 1. VA New York Harbor Healthcare System, New York University, New York, NY, USA. 2. Perlmutter Cancer Center, New York University, New York, NY, USA. 3. Department of Urology, New York University, New York, NY, USA. 4. Department of Population Health, New York University, New York, NY, USA. 5. VA Puget Sound Healthcare System and University of Washington, Seattle, WA, USA. 6. Department of Population Health Sciences, University of Utah School of Medicine, Salt Lake City, UT, USA. 7. Salt Lake City VA Center for Informatics Decision Enhancement and Surveillance (IDEAS), Salt Lake City, UT, USA. 8. Robert F. Wagner Graduate School of Public Service, New York University, New York, NY, USA.
Abstract
BACKGROUND: In 2012, the United States Preventative Services Task Force (USPSTF) formally recommended against all prostate-specific antigen (PSA) screening for prostate cancer. Our goal was to characterize PSA screening trends in the Veterans Health Administration (VA) before and after the USPSTF recommendation and to determine if PSA screening was more likely to be ordered based on a veteran's race or age. METHODS: Using the VA Corporate Data Warehouse, we created 10 annual groups of PSA-eligible men covering 2009-2018. We identified all PSA tests performed in the VA to determine yearly rates of PSA screening. All statistical tests were 2-sided. RESULTS: The overall rate of PSA testing in the VA decreased from 63.3% in 2009 to 51.2% in 2018 (P < .001). PSA screening rates varied markedly by age group during our study period, with men aged 70-80 years having the highest initial rate and greatest decline (70.6% in 2009 to 48.4% in 2018, P < .001). Men aged 55-69 years had a smaller decline (65.2% in 2009 to 58.9% in 2018, P < .001) whereas the youngest men, aged 40-54 years, had an increase in PSA screening (26.2% in 2009 to 37.8% in 2018, P < .001). CONCLUSIONS: In this analysis of PSA screening rates among veterans before and after the 2012 USPSTF recommendation against screening, we found that overall PSA screening decreased only modestly, continuing for more than one-half of the men in our study. Veterans of different races had similar screening rates, suggesting that VA care may minimize racial disparities. Veterans of varying ages experienced statistically significantly differences in PSA screening trends. Published by Oxford University Press 2020.
BACKGROUND: In 2012, the United States Preventative Services Task Force (USPSTF) formally recommended against all prostate-specific antigen (PSA) screening for prostate cancer. Our goal was to characterize PSA screening trends in the Veterans Health Administration (VA) before and after the USPSTF recommendation and to determine if PSA screening was more likely to be ordered based on a veteran's race or age. METHODS: Using the VA Corporate Data Warehouse, we created 10 annual groups of PSA-eligible men covering 2009-2018. We identified all PSA tests performed in the VA to determine yearly rates of PSA screening. All statistical tests were 2-sided. RESULTS: The overall rate of PSA testing in the VA decreased from 63.3% in 2009 to 51.2% in 2018 (P < .001). PSA screening rates varied markedly by age group during our study period, with men aged 70-80 years having the highest initial rate and greatest decline (70.6% in 2009 to 48.4% in 2018, P < .001). Men aged 55-69 years had a smaller decline (65.2% in 2009 to 58.9% in 2018, P < .001) whereas the youngest men, aged 40-54 years, had an increase in PSA screening (26.2% in 2009 to 37.8% in 2018, P < .001). CONCLUSIONS: In this analysis of PSA screening rates among veterans before and after the 2012 USPSTF recommendation against screening, we found that overall PSA screening decreased only modestly, continuing for more than one-half of the men in our study. Veterans of different races had similar screening rates, suggesting that VA care may minimize racial disparities. Veterans of varying ages experienced statistically significantly differences in PSA screening trends. Published by Oxford University Press 2020.
Authors: Steven B Zeliadt; Richard M Hoffman; Ruth Etzioni; John L Gore; Larry G Kessler; Daniel W Lin Journal: J Natl Cancer Inst Date: 2011-02-28 Impact factor: 13.506
Authors: Andrew M D Wolf; Richard C Wender; Ruth B Etzioni; Ian M Thompson; Anthony V D'Amico; Robert J Volk; Durado D Brooks; Chiranjeev Dash; Idris Guessous; Kimberly Andrews; Carol DeSantis; Robert A Smith Journal: CA Cancer J Clin Date: 2010-03-03 Impact factor: 508.702
Authors: R A Smith; A C von Eschenbach; R Wender; B Levin; T Byers; D Rothenberger; D Brooks; W Creasman; C Cohen; C Runowicz; D Saslow; V Cokkinides; H Eyre Journal: CA Cancer J Clin Date: 2001 Jan-Feb Impact factor: 508.702
Authors: Nancy C Dolan; M Rosario Ferreira; Marian L Fitzgibbon; Terry C Davis; Alfred W Rademaker; Dachao Liu; June Lee; Michael Wolf; Brian P Schmitt; Charles L Bennett Journal: Am J Prev Med Date: 2005-06 Impact factor: 5.043
Authors: Kirsten L Greene; Peter C Albertsen; Richard J Babaian; H Ballentine Carter; Peter H Gann; Misop Han; Deborah Ann Kuban; A Oliver Sartor; Janet L Stanford; Anthony Zietman; Peter Carroll Journal: J Urol Date: 2009-09-24 Impact factor: 7.450
Authors: Afshin Aslani; Brian J Minnillo; Ben Johnson; Edward E Cherullo; Lee E Ponsky; Robert Abouassaly Journal: J Urol Date: 2013-12-14 Impact factor: 7.450
Authors: Michael S Leapman; Kimberly Stone; Roxanne Wadia; Lesley S Park; Cynthia L Gibert; Matthew B Goetz; Roger Bedimo; Maria Rodriguez-Barradas; Fatma Shebl; Amy C Justice; Sheldon T Brown; Kristina Crothers; Keith M Sigel Journal: J Urol Date: 2021-09-24 Impact factor: 7.600